FDA grants expanded approval for Merck’s lung cancer drug Keytruda (MRK)

IvelinRadkov

The FDA has granted expanded approval for Merck’s (NYSE:MRK) oncology drug Keytruda in the treatment of non-small cell lung cancer, or NSCLC.

Keytruda, also known as pembrolizumab, was approved as a neoadjuvant and post-surgical adjuvant for patients with resectable NSCLC, according to Bloomberg.

ApprovalcancerdrugexpandedFDAGrantsKeytrudalungMercksMRK
Comments (0)
Add Comment